The Company does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for adjusted EBITDA, adjusted earnings per share, adjusted operating income and free cash flow, to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. Develop and implement solutions to end plastic waste while supporting AEPW $1.5B investment in key initiatives. 2030 SUSTAINABILITY TARGETS 15 PEER COMPARISONS 16 $442 $457 $560 2019PF 2020PF 2021E $1.74 $1.93 $2.80 2019PF 2020PF 2021E FULL YEAR 2019 – 2021 ORGANIC GROWTH (TOTAL COMPANY) 17 Sales Adjusted EBITDA $3,981 $3,783 $4,300 2019PF 2020PF 2021E + 8% Adjusted EPS (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (1) (1) (in millions) (in millions) (1)(1) + 27% + 61% (1) (1) As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers.

D is t. ) K W R P P G F U L R P M A V Y F M C H U N H X L S C L E C L E M N C E A S H Source: Peer data per Bloomberg market data as of February 15, 2022. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $635M and estimated CAPEX of $90M (excludes IT system upgrade of $25M and synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of February 15, 2022 86 89 85 80 76 76 89 85 79 78 76 76 76 70 69 63 8 A vi e nt K W R P P G F U L A V Y R P M F M C U N V R H U N B N R H X L E C L C E A S H E M N S C L A LB Source: Peer data per Bloomberg market data as of February 15, 2022 Total Enterprise Value / 2022E EBITDAWith the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets. Over the last 10 years, our multiple has expanded as we have progressed in our portfolio transformation.

The Company does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for Adjusted EBITDA, Adjusted Earnings Per Share, Adjusted Operating Income and Free Cash Flow, to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. D is t. ) K W R P P G A V Y F U L R P M G C P H X L F M C H U N IF F E C L A S H K R A E M N C E S C L A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of July 28, 2021 Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 81% Median: 78% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of July 28, 2021 87 90 86 82 80 78 73 87 82 82 79 79 78 78 77 76 71 67 46 A vi en t K W R P P G A V Y F U L R P M G C P F M C U N V R C E IF F A S H E C L B N R E M N H X L H U N K R A S C L A L B (6) Source: Peer data per Bloomberg market data as of July 28, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies.

Our 2024 injury incident rate was an all-time record low and reflective of the safest year in our company’s history. Last year, prominent third-party ratings and ranking firms recognized our ongoing improvements. Management excludes intangible asset amortization from adjusted EPS as it believes excluding acquired intangible asset amortization is a useful measure of current period earnings per share.

The Company does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for Adjusted EBITDA, Adjusted Earnings Per Share, Adjusted Operating Income and Free Cash Flow, to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of October 25, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of October 25, 2021 86 92 85 82 79 77 74 89 83 82 80 79 79 78 78 72 33 A vi en t K W R P P G A V Y F U L R P M G C P F M C U N V R C E H X L B N R A S H E C L E M N H U N S C L A L B (12) Source: Peer data per Bloomberg market data as of October 25, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies.

Is or has been an employee of the Company within the past three years, or has an immediate family member who is or has been an executive officer of the Company within the past three years; B. Has been, or has an immediate family member who has been, within the last three years, a partner or employee of the Company’s internal or external auditor and personally worked on the Company’s audit within that time; F. Directors are expected to comply with this requirement within five years of becoming a director.

Second quarter GAAP and adjusted earnings per share (EPS) were $0.24 and $0.63, respectively. We are maintaining our full year adjusted EPS guidance of $2.40 on lower estimated sales of $3.3 billion,” said Mr. Avient will share further information regarding second quarter results and full-year guidance during its previously scheduled webcast at 8:00 a.m.

The non-GAAP financial measures include: Adjusted Earnings Per Share, Net Debt / Adjusted EBITDA, and Adjusted EBITDA. Prior Year 14 Q4 2023 PERFORMANCE VS. Management excludes intangible asset amortization from adjusted EPS as it believes excluding acquired intangible asset amortization is a useful measure of current period earnings per share.

With more than 27 years of experience in the specialty polymer sector, Mr. Over the last three years, over the last 12 years.